Trial Profile
A double-blind, randomized, placebo-controlled, proof of concept study to investigate the differences between the combined administration of 0.5 mg sublingual testosterone and 10 mg buspirone and 10 mg buspirone administration alone in women with hypoactive sexual desire disorder
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2014
Price :
$35
*
At a glance
- Drugs Buspirone/testosterone (Primary) ; Buspirone
- Indications Female sexual dysfunction
- Focus Therapeutic Use
- Acronyms EB93 PoC
- Sponsors Emotional Brain
- 04 Sep 2012 New trial record